返回
公司介紹
董事會
管理團隊
合作伙伴
企業(yè)榮譽
專利布局
納基奧侖賽
認證醫(yī)療機構(gòu)名單
創(chuàng)新支付
研發(fā)管線
學術(shù)發(fā)表
公司新聞
產(chǎn)品新聞
媒體報道
企業(yè)文化
招賢納士
Development of a Novel Allogeneic Super-γδ T Cell Therapy for Acute Myeloid Leukemia and Multiple Tumors
Efficacy and Safety of Inaticabtagene Autoleucel in Children with Relapsed/Refractory (R/R) B-cell Acute Lymphoblastic Leukemia in China
Inaticabtagene Autoleucel (CNCT19) in Adult Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
CD19 CAR T-Cell Therapy in Refractory Autoimmune Hemolytic Anemia
Development of Allogeneic Dual-Targeting CD19/BCMA CAR-T Cell Therapeutics Using ALL-IN-ONE Site-Specific Integration Technology for Autoimmune Diseases
Sustained Remission and Decreased Severity of CAR T-Cell Related Adverse Events: An Updated Report on the Pivotal Study of Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-Cell ALL) in China
010-65960020
pr@juventas.cn
查看更多 +